Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health
Download Here

Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion and exon 21 L858R.This PQI aims to provide guidance for initiating therapy with osimertinib. Continue reading Osimertinib (Tagrisso) in EGFR Positive NSCLC

Read More

Seattle Genetics, Inc. is pleased to inform you that on April 17, 2020, the FDA approved TUKYSA tablets for oral administrationTUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Please see attached full Prescribing Information HERE

Below is the product information needed to load TUKYSA.

NDC

51144-002-60

TUKYSA

(tucatinib) 150mg

Yellow, caplet-shaped tablet

TUC embossed on one side, 150 on other side

60 count tablets/bottle

NDC

51144-001-60

TUKYSA

(tucatinib) 50mg

Yellow, round-convex tablet

TUC embossed on one side, 50 on other side

60 count tablets/bottle

TUKYSA can be ordered through the following Specialty Distributors:

ASD Healthcare

McKesson Plasma & Biologics

Cardinal Health

McKesson Specialty Health

Oncology Supply

Click here to learn more.

Read More

In light of the developing situation around COVID-19, we would like to share immediate action Bristol Myers Squibb is taking to support the health and well-being of patients, customers and employees during this time. Bristol Myers Squibb is expanding its longstanding patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic. The expanded program offers access to BMS medicine for free. Read more here or download patient-support-program-overview

 

Read More

MISSION STATEMENT/PHILOPSOPHY:

Clearview Cancer Institute is committed to providing cutting edge quality, compassionate, comprehensive care.

LOCATION(S):

Anniston Location, Athens Location, Cullman Location, Decatur Location, Florence Location, Huntsville-Crestwood Location, Huntsville- Main Location, Jasper Location, Scottsboro Location

PRACTICE DETAILS (how many providers, how many employees, etc):

Clearview Cancer Institute Consists of 22 Physicians and 20 APP’s

QUALIFICATIONS/CREDENTIALS (are you QOPI certified, etc.)

Our Retail Pharmacy is ACHC and URAC Certified

INTRODUCTION TO PHARMACY SERVICES STAFF W/ BRIEF BIO:

Our Pharmacy Staff consists of 2 Full Time Pharmacists and 4 Pharmacy Technicians. First Photo- Current Pharmacy Staff, Second Photo- Pharmacist (Meg) and I at NCODA Fall Summit 2018

DISPENSING TYPE (RETAIL VS DISPENSARY)

Retail Pharmacy

SERVICES PROVIDED (BONE MARROW, RADIATION, CHEMO)

Clearview Cancer Institute offers Diagnostic Imaging, Genetic Testing, Genetic Counseling, Genomic Testing, Hematology, Lab Services, Lung Cancer Screening, Medical Oncology, Outpatient Therapy, Pharmacy, and Radiation Oncology. Plans to open our Palliative Care Clinic later this year.

WHY DID  YOU JOIN NCODA?

I joined NCODA to discover new ways to help contribute to our pharmacy and clinic.

HOW DID YOU BECOME A MEMBER?

I became a member by applying online at NCODA’s website.

HOW DID YOU HEAR ABOUT US?

My Pharmacist at the time encouraged me to get involved with NCODA.

HOW CAN NCODA HELP YOU?

NCODA helps me meet new people with common goals, we are able to learn and grow from each other.

WHAT ARE SOME CHALLENGES YOU FACE NOW OR WILL FACE IN THE FUTURE OF ONCOLOGY?

Right now, I think a challenge we are all facing is the current COVID19 Pandemic. We are making the best out of the situation while making sure that our patients are receiving the best care they can while given the circumstances.

Read More